BioCentury
ARTICLE | Clinical News

Avelumab: Phase III started

November 23, 2015 8:00 AM UTC

Merck and Pfizer began the open-label, international Phase III JAVELIN lung 100 trial to compare 10 mg/kg IV avelumab every 2 weeks vs. investigator’s choice of platinum-based chemotherapy in about 42...